-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BMO Capital Downgrades Fate Therapeutics to Market Perform, Lowers Price Target to $7

Benzinga · 01/06/2023 05:02
BMO Capital analyst Etzer Darout downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform and lowers the price target from $20 to $7.